articleTop 10% cited
The C679X mutation in PCSK9 is present and lowers blood cholesterol in a Southern African population
Atherosclerosis · 2006 · Vol. 193(2) · pp. 445–448
Amanda J. Hooper(Royal Perth Hospital)A. David Marais(University of Cape Town)Donald Moshen Tanyanyiwa(University of Cape Town)John R. Burnett✉(University of Western Australia)
Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and LipoproteinsCholesterol and Lipid MetabolismPCSK9Missense mutationKexinProprotein convertaseNonsense mutationPopulationCholesterolInternal medicineEndocrinologyMedicine
MeSH terms
Proprotein Convertase 9AdultFemaleGenotypeHumansHyperlipoproteinemia Type IICholesterol, LDLSerine EndopeptidasesZimbabweCodon, NonsenseGenetic Predisposition to DiseaseProprotein Convertases
Funding
- National Heart Foundation of Australia
- Raine Medical Research Foundation
- South African Medical Research Council
Citations
363
FWCI
9.11
field-weighted impact
References
25
Percentile
98%
vs. same field & year
Citations per year
Cited by
PCSK9: a convertase that coordinates LDL catabolism
Journal of Lipid Research · 2008 · 625 citations
References
Mutations in PCSK9 cause autosomal dominant hypercholesterolemia
Nature Genetics · 2003 · 2,977 citations
Statins Upregulate <i>PCSK9</i> , the Gene Encoding the Proprotein Convertase Neural Apoptosis-Regulated Convertase-1 Implicated in Familial Hypercholesterolemia
Arteriosclerosis Thrombosis and Vascular Biology · 2004 · 600 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.